Your shopping cart is currently empty

LCKLSL hydrochloride is a hexapeptide compound and competitive inhibitor of membrane-bound protein A2 (AnxA2) with potential anti-angiogenic activity that inhibits the development of autoimmune encephalomyelitis (EAE) in mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $84 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $372 | - | In Stock | |
| 25 mg | $689 | - | In Stock | |
| 50 mg | $979 | - | In Stock | |
| 100 mg | $1,320 | - | In Stock | |
| 200 mg | $1,780 | - | In Stock |
| Description | LCKLSL hydrochloride is a hexapeptide compound and competitive inhibitor of membrane-bound protein A2 (AnxA2) with potential anti-angiogenic activity that inhibits the development of autoimmune encephalomyelitis (EAE) in mice. |
| In vitro | In human retinal microvascular endothelial cells (RMVEC), treatment with LCKLSL hydrochloride (0-2 mg) inhibited the production of fibrinolytic enzymes and suppressed VEGF-induced tPA activity under hypoxic conditions. [1] |
| In vivo | In two in vivo models of angiogenesis (chicken chorioallantoic membrane and mouse stromal plug assay), the application of LCKLSL hydrochloride showed an inhibitory effect on the angiogenic response. After LCKLSL hydrochloride peptide treatment, the length of blood vessels was significantly shortened. At a dose of 5 μg/mL, LCKLSL hydrochloride peptide significantly reduced the number of branches, junctions, and endpoints of vessels. [1] |
| Molecular Weight | 712.34 |
| Formula | C30H58ClN7O8S |
| Smiles | CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O.Cl |
| Sequence | Leu-Cys-Lys-Leu-Ser-Leu |
| Sequence Short | LCKLSL |
| Storage | keep away from moisture,store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: 8 mg/mL (11.23 mM), Sonication is recommended. DMSO: 20 mg/mL (28.08 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | Saline: 2 mg/mL (2.81 mM), Solution Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.